The Lynx Group

Gasterol Intestinal Symposium

San Francisco, CA—Using a prediction model to analyze the impact of adding targeted agents to the treatment of pancreatic neuroendocrine tumors (pNETs), everolimus (Afinitor) had a minimal overall impact on healthcare expenditures, by reducing infusions and surgical procedures costs, according to a study presented at the 2012 Gastrointestinal Cancers Symposium.
Read Article

San Francisco, CA—For resectable pancreatic cancer, administering chemo - therapy and radiation before surgery results in better outcomes and lower costs than performing surgery first, reported researchers from M.D. Anderson Cancer Center, Houston.
Read Article

San Francisco, CA—Results obtained on the Oncotype DX Colon Cancer Assay led to changes in treatment decisions 29% of the time for patients with stage II colon cancer, according to a survey of community oncologists reported at the 2012 Gastrointestinal Cancers Symposium.
Read Article

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: